BridgeBio Pharma, Inc.NASDAQ: BBIO

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

· Issued by BridgeBio Pharma, Inc.

On 6ix: 6ix.com/news/bridgebio-pharma-reports-second-quarter-2023-financial-results-and-business-update

Watch BridgeBio Pharma's latest callBridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Bridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call
BridgeBio Pharma's next earnings callBridgebio Pharma (NASDAQ:BBIO) Q3 2026 Earnings Call · Oct 29, 2026 at 4:30 PM EDTRegister

- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p

BridgeBio Pharma, Inc. on 6ix

Story so far

Earlier from BridgeBio Pharma

Later from BridgeBio Pharma

All BridgeBio Pharma news releases